China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has announced that its second-generation transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty, has received marketing approval from the Turkish Medicines and Medical Devices Agency (TITCK). This marks another global milestone for the product, following its approval in multiple countries and regions, most recently in South Korea.
VitaFlow Liberty: A Pioneering TAVI System
VitaFlow Liberty, the world’s only electric recyclable TAVI system, was first approved in China in 2021. The product features a mixed density self-expanding stent, bovine pericardial leaflets, and a high bilayer PET skirt design, which contribute to its excellent performance. VitaFlow Liberty offers high radial support, better coaxial release, and effectively reduces the postoperative valve leakage rate.
Global Impact of CardioFlow’s VitaFlow Series
As of now, CardioFlow’s VitaFlow series products, along with its Alwide balloon series accessory products, have been implemented in over 700 core hospitals across more than 20 countries. The products have treated more than 10,000 patients with aortic valve diseases worldwide, demonstrating the global reach and impact of MicroPort CardioFlow Medtech’s innovative solutions in the field of cardiovascular medicine.-Fineline Info & Tech
